27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
On 25 October 2021, the marketing authorization holder for dapagliflozin withdrew the indication for type 1 diabetes across Europe and the U.K. The SGLT2 inhibitor dapagliflozin has been indicated for the treatment of type 2 diabetes since 2012.
- AstraZeneca Plc's (NASDAQ:AZN) dapagliflozin 5mg (Forxiga/Farxiga) was authorized in 2019 as an adjunct to insulin in patients with type 1 diabetes with a body-mass index (BMI) of 27 kg per m2.
- The decision to voluntarily withdraw the indication in type 1 diabetes followed commercial considerations due to a specific European-wide regulatory requirement for this authorization.
- The decision was not driven by any new safety concerns.
- Other indications for dapagliflozin 5mg and 10mg are not affected by this change, and both strengths will remain on the market.
- Dapagliflozin remains authorized in adults for type 2 diabetes, symptomatic chronic heart failure with reduced ejection fraction, and chronic kidney disease.
- Price Action: AZN shares are down 1.68% at $54.04 during the market session on the last check Friday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!